Physician’s Weekly: PCAT: an integrated portal for genomic and preclinical testing data of pediatric cancer patient-derived xenograft models.
August 20, 2020
Although cancer is the leading cause of disease-related mortality in children, the relative rarity of pediatric cancers poses a significant challenge for developing novel therapeutics to further improve prognosis. Patient-derived xenograft (PDX) models, which are usually developed from high-risk tumors, are a useful platform to study molecular driver events, identify biomarkers and prioritize therapeutic agents.
